REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85%
Replimune Group (REPL) shares dropped 60% after the FDA rejected its melanoma treatment, RP1, for the second time. The company may scale back operations. Jefferies cut its price target to $2 from $13, and JPMorgan downgraded the stock to 'Underweight'.
How this was made
The 30-second read
Why it matters
The denial eliminates the company's near‑term revenue catalyst, likely driving the stock to record lows.
Market read
Immediate negative impact on REPL; broader biotech sentiment may soften.
What to watch
Potential for a resubmission or acquisition interest could mitigate downside.
Background
Replimune Group announced a second FDA rejection of its RP1 melanoma therapy, prompting analyst downgrades and price‑target cuts.
Ticker impact
FDA rejected Replimune's melanoma therapy RP1, causing a 60% pre‑market plunge.
Sharp sell‑off, likely further downside toward low single‑digit levels.
Regulatory denial removes the primary growth catalyst; analysts have cut price targets and downgraded the stock.
Market effects
Biotech sector may see broader risk aversion toward melanoma immunotherapy candidates.
U.S. biotech stocks could face heightened volatility in early trading.
Limited to U.S. listed biotech; no immediate global macro effect.
Counterpoint
If the company can secure a new indication or partner, the stock may rebound from oversold levels.
Key entities
- companyReplimune Group, Inc.
Biotech firm developing RP1 melanoma therapy.
- regulatorU.S. Food and Drug Administration
Agency that denied the drug approval.